Results 131 to 140 of about 209,011 (190)

Hyperlipidemia and inhibitors of HIV protease

Current Opinion in Clinical Nutrition and Metabolic Care, 2001
HIV protease inhibitors have been successfully incorporated into therapy for patients with HIV. These otherwise efficacious treatments present with multiple metabolic side-effects and body habitus changes known as the lipodystrophy syndrome. Direct associations of the lipid abnormalities with protease inhibitor use have been described, and ongoing ...
O, Distler, D A, Cooper, R J, Deckelbaum, S L, Sturley   +3 more
openaire   +2 more sources

Prodrugs of HIV Protease Inhibitors

Current Pharmaceutical Design, 2003
Despite the efficiency of the present polytherapies against AIDS, HIV replication continues indicating difficulties in drug adherence, drug-drug interactions, resistance issues, and the existence of reservoirs or sanctuaries for the virus. Moreover, most of the current FDA-approved HIV protease inhibitors (PIs) display disadvantageous physicochemical ...
Pierre, Vierling, Jacques, Greiner
openaire   +2 more sources

Peptidomimetic Inhibitors of HIV Protease

Current Topics in Medicinal Chemistry, 2004
There are currently (July, 2002) six protease inhibitors approved for the treatment of HIV infection, each of which can be classified as peptidomimetic in structure. These agents, when used in combination with other antiretroviral agents, produce a sustained decrease in viral load, often to levels below the limits of quantifiable detection, and a ...
John T, Randolph, David A, DeGoey
openaire   +2 more sources

Inhibitors of HIV-1 Protease

Journal of Enzyme Inhibition, 1992
The human immunodeficiency virus (HIV), the etiological agent for the acquired immune deficiency syndrome (AIDS), is a retrovirus which makes use of a virally-encoded aspartic protease to perform specific proteolytic processing of two of its gene products in order to form active enzymes and structural proteins within the mature virion.
openaire   +2 more sources

Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.

Current Topics in Medicinal Chemistry, 2019
Acquired Immunodeficiency Syndrome (AIDS) is a chronic disease characterized by multiple life-threatening illnesses caused by a retro-virus, Human Immunodeficiency Virus (HIV).
Chandrashekhar Voshavar
semanticscholar   +1 more source

Perspectives in HIV Protease Inhibitors

1996
The therapy of HIV-1, the causative agent of AIDS, is limited today to a small number of different drugs, all of which are nucleoside analogues. Nucleoside analogues active against HIV are all inhibitors of reverse transcriptase (RT) and target primarily early events in the replication cycle of HIV.
openaire   +2 more sources

HIV Protease Inhibitors: Present and Future

Future Virology, 2011
Antiretroviral therapy offers many options, largely based on the next-generation protease inhibitors (PIs). Early PI-based treatments involve high pill burdens and dosing schedules, and concerns of long-term toxicities are well established. In patients who have already achieved viral suppression, novel agents and strategies should be used to simplify ...
Pizzocolo Cecilia, Castagna A, Lazzarin Adriano   +2 more
openaire   +1 more source

The synthesis of novel HIV-protease inhibitors

Bioorganic & Medicinal Chemistry, 1994
The syntheses, enzyme inhibition and antiviral activity of potent HIV-protease inhibitors containing novel beta-hydroxy ether and thioethers based on the transition state mimetic concept are discussed.
V M, Girijavallabhan, F, Bennett, N M, Patel, A K, Ganguly, B, Dasmahapatra, N, Butkiewicz, A, Hart   +6 more
openaire   +2 more sources

Oral Delivery of HIV-Protease Inhibitors

Critical Reviews™ in Therapeutic Drug Carrier Systems, 2000
Strategies for optimizing the oral delivery of HIV-protease inhibitors draw from drug discovery efforts in molecular design, drug development tools in dosage formulation, and dosage regimen considerations in clinical medicine. This review outlines the evolution of these strategies for drugs that have been approved for human use, drug candidates still ...
L Y, Li, B H, Stewart, D, Fleisher
openaire   +2 more sources

Drug Interactions of HIV Protease Inhibitors

Drug Safety, 1999
All the currently available protease inhibitors are metabolised by the cytochrome P450 (CYP) enzyme system. All are inhibitors of CYP3A4, ranging from weak inhibition for saquinavir to very potent inhibition for ritonavir. Thus, they are predicted to have numerous drug interactions, although few such interactions have actually been documented either in
L I, Malaty, J J, Kuper
openaire   +2 more sources